Teva price target raised to $13 from $12 at BofA

BofA analyst Jason Gerberry raised the firm’s price target on Teva to $13 from $12 and keeps a Buy rating on the shares after offering updated views on key investor debates within the analyst’s CNS coverage. The U.S. long acting injectable schizophrenia market “remains attractive” and the firm came away from recent checks with key opinion leaders “encouraged” that recently launched Uzedy offers enough clinical differentiation on dosing format to gain traction, the analyst tells investors.